Bailey Quoted in The Bond Buyer about Proposed Regulations Impacting Municipal Market
02 January 2019
Partner Michael Bailey was quoted in The Bond Buyer article, “Treasury Finalizes PaB rRG, Proposed Re-Issuance Reg,” about two long-awaited regulatory steps that will impact the municipal market. The Treasury Department and the Internal Revenue Service published final public notice requirements for issuing private activity bonds and a proposed regulation clarifying when tax-exempt bonds require re-issuance. The final regulations simplify the public notice and approval requirements for PAB issuance. They do not, however, drop the requirement for a public hearing in certain circumstances.
Bailey said the regulations were a welcome development. “They were, in many ways, responsive to the comments,” said Bailey, who is a board member of the National Association of Bond Lawyers. The NABL had requested that the public notice requirement be reduced to seven days.
(Subscription Required)
Bailey said the regulations were a welcome development. “They were, in many ways, responsive to the comments,” said Bailey, who is a board member of the National Association of Bond Lawyers. The NABL had requested that the public notice requirement be reduced to seven days.
(Subscription Required)
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”